Form 4: Kineta Chief Scientific Officer Exercises Options and Adjusts Holdings Amidst TuHURA Merger

Kineta, Inc.'s Chief Scientific Officer, Thierry Guillaudeux, reported significant stock transactions, including the exercise of options and subsequent share dispositions, tied to the company's merger agreement with TuHURA Biosciences, Inc.

Summary

• Thierry Guillaudeux, Kineta, Inc.'s Chief Scientific Officer, reported changes in his beneficial ownership of common stock.
• On June 23, 2025, Mr. Guillaudeux exercised stock options to acquire 225,000 shares of common stock at an exercise price of $0.36 per share.
• Concurrently on June 23, 2025, 47,647 shares were disposed of at a price of $0.26 per share, likely for tax withholding purposes related to the option exercise.
• On June 25, 2025, an additional 23,100 shares of common stock were acquired at a price of $0.
• Following these transactions, Mr. Guillaudeux's direct beneficial ownership of common stock changed from 246,696 shares to 194,233 shares after the disposition, and then increased to 217,333 shares after the subsequent acquisition.
• The stock options became fully vested on June 23, 2025, pursuant to an Optionholder Treatment Agreement and the Agreement and Plan of Merger with TuHURA Biosciences, Inc., which was approved by Kineta's stockholders on the same date.

Sentiment

Score: 5

Explanation: The document is a factual report of insider stock transactions and does not inherently convey positive or negative sentiment regarding the company's performance, beyond the routine nature of option exercises and tax-related dispositions during a merger process.

Positives

• The Chief Scientific Officer's stock options became fully vested, indicating a milestone achievement related to the merger agreement.
• The exercise of 225,000 stock options demonstrates the executive's continued investment in the company.

Negatives

• A significant number of shares (47,647) were disposed of, likely to cover tax obligations arising from the option exercise, which reduces the executive's direct holdings.

Future Outlook

The document indicates the ongoing process of the merger between Kineta, Inc. and TuHURA Biosciences, Inc., with the merger agreement having been approved by Kineta's stockholders. This suggests the merger is progressing towards completion.

Industry Context

This Form 4 filing reflects an insider transaction within the biotechnology or pharmaceutical industry, specifically related to a merger and acquisition (M&A) event. Such transactions are common during corporate restructuring or M&A activities, as executive compensation and equity plans are often adjusted or accelerated in anticipation of or following such events. The vesting of options tied to a merger agreement is a standard practice to align executive incentives with shareholder interests during a corporate transaction.

Corporate Governance

Related Party Transactions

• The transactions involve the Chief Scientific Officer of Kineta, Inc., an insider, exercising stock options and adjusting his beneficial ownership, which is a common type of related party transaction in the context of executive compensation.

Stakeholder Impact

• Shareholders: The merger agreement, which triggered the option vesting, directly impacts shareholders by potentially changing the company's structure and future prospects. The insider's stock activity provides transparency into executive holdings.
• Employees (specifically the CSO): The vesting and exercise of options represent a realization of value from their equity compensation.

Next Steps

• Completion of the merger between Kineta, Inc. and TuHURA Biosciences, Inc., as the merger agreement has been approved by Kineta's stockholders.

Key Dates

Keywords

Kineta, KANT, TuHURA Biosciences, SEC Form 4, Insider Trading, Stock Options, Beneficial Ownership, Merger Agreement, Equity Incentive Plan, Chief Scientific Officer